| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882916 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 6 Pages |
Abstract
Imatinib completely blunts tubular secretion of creatinine, a previously unreported pharmacologic property. This inhibition increases serum creatinine independently of any glomerular dysfunction and is fully reversible on imatinib cessation.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Emmanuelle Vidal-Petiot, Delphine Rea, Fidéline Serrano, Thomas Stehlé, Claude Gardin, Philippe Rousselot, Marie-Noëlle Peraldi, Martin Flamant,